Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.
Protara Therapeutics, Inc. TARA shares are down during Tuesday’s premarket session following the release of updated interim ...
A noninvasive urinary DNA methylation test demonstrated high sensitivity for detecting high-grade or invasive bladder cancer. A urinary DNA methylation test displayed superior sensitivity for ...
Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...
Protara Therapeutics (NASDAQ:TARA) on February 23, 2026, announced updated interim data from its ongoing Phase 2 ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsCompany expects to complete enrollment of ...
Colorado Buffaloes head coach Deion Sanders revealed he underwent bladder removal surgery earlier this year after being diagnosed with high-grade bladder cancer. His oncologist has since declared him ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results